• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
CONCLUSION: Overall, our study revealed that METTL3 functions as an oncogene in the growth and invasion of osteosarcoma by regulating ATAD2, suggesting a potential therapeutic target for osteosarcoma treatment. PMID: 32044716 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 6, 2020 Category: Drugs & Pharmacology Authors: Zhou L, Yang C, Zhang N, Zhang X, Zhao T, Yu J Tags: Biomed Pharmacother Source Type: research

Knockdown of 91 H Suppresses the Tumorigenesis of Osteosarcoma via Inducing Methylation of CDK4 Promoter.
CONCLUSION: knockdown of 91 H suppressed the tumorigenesis of osteosarcoma via inducing methylation of CDK4 promoter in vitro and in vivo. Thus, 91 H may serve as a new target for the treatment of osteosarcoma. PMID: 33499776 [PubMed - in process]
Source: Technology in Cancer Research and Treatment - January 1, 2021 Category: Cancer & Oncology Authors: Cheng S, Zheng J, Liu X, Shi J, Gong F, Zhang X, Liu C, Liu C Tags: Technol Cancer Res Treat Source Type: research

Knockdown of 91 H Suppresses the Tumorigenesis of Osteosarcoma via Inducing Methylation of CDK4 Promoter
CONCLUSION: knockdown of 91 H suppressed the tumorigenesis of osteosarcoma via inducing methylation of CDK4 promoter in vitro and in vivo. Thus, 91 H may serve as a new target for the treatment of osteosarcoma.PMID:33499776 | PMC:PMC7844445 | DOI:10.1177/1533033821990006
Source: Technology in Cancer Research and Treatment - January 27, 2021 Category: Cancer & Oncology Authors: Suoli Cheng Jianping Zheng Xueqin Liu Jiandang Shi Fan Gong Xu Zhang Changhao Liu Cuiyun Liu Source Type: research

Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression
ConclusionOur results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.
Source: Cancer Chemotherapy and Pharmacology - June 10, 2021 Category: Cancer & Oncology Source Type: research

ATRX loss suppresses the type I interferon response in sarcoma cells through chromatin remodeling
Am J Cancer Res. 2023 Aug 15;13(8):3547-3558. eCollection 2023.ABSTRACTSarcomas constitute a heterogeneous group of mesenchymal cancers and are particularly common in children and adolescents, leading to significant lethality. Therefore, it is necessary to understand the underlying mechanisms by which genetic alterations promote sarcoma progression. Here, we demonstrate that loss-of-function of ATRX, a member of the SWI/SNF DNA-remodeling family, represses the interferon (IFN)-β response by inducing chromatin remodeling in sarcoma cells. We show that ATRX mutations are associated with worse prognosis and attenuate IFN-α/...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Xinrui Wang Zige Jin Shanshan Tang Xiyu Huang Shanshan Wang Xiaohe Ren Mafei Xu Source Type: research

Pages: 1  2